A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors

NCT00001495 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: irinotecan (CPT-11)

Sponsor

National Cancer Institute (NCI)